Table 1 Comparison of patient, tumour, and treatment characteristics among the four broad ethnic groups of women aged 18–39 years with breast cancer
Characteristic | Non-Hispanic white ( n =35 101) | Black ( n =8215) | Hispanic white ( n =7067) | Asian ( n =4770) | P- value |
|---|---|---|---|---|---|
Disease stage | <0.0001a | ||||
Localised | 17 602 (51.6) | 3538 (44.3) | 3035 (44.3) | 2477 (52.9) | |
Regional | 14 936 (43.8) | 3785 (47.4) | 3356 (48.9) | 1978 (42.3) | |
Distant | 1581 (4.6) | 659 (8.3) | 465 (6.8) | 225 (4.8) | |
Unknown | 982 | 233 | 211 | 90 | |
Age at diagnosis (years) | 0.0001b | ||||
Mean (median) | 35 (36) | 34.4 (35) | 34.5 (35) | 35 (36) | |
<35 years | 12 421 (35.4) | 3499 (42.6) | 2930 (41.5) | 1718 (36.0) | <0.0001 |
⩾35 years | 22 680 (64.6) | 4716 (57.4) | 4137 (58.5) | 3052 (64.0) | |
Surgery | <0.0001a | ||||
No primary surgery | 1030 (3.0) | 583 (7.2) | 477 (6.8) | 175 (3.7) | |
SM | 11 835 (34.2) | 2929 (36.2) | 2584 (36.9) | 1775 (37.5) | |
TM | 21 731 (62.8) | 4584 (56.6) | 3948 (56.3) | 2780 (58.8) | |
Unknown | 505 | 119 | 58 | 40 | |
Tumour grade | <0.0001a | ||||
I | 1816 (7.3) | 278 (4.6) | 336 (5.7) | 336 (8.8) | |
II | 7905 (31.8) | 1521(24.9) | 1744 (29.5) | 1338 (35.0) | |
III | 14 045 (56.4) | 4079 (66.8) | 3553 (60.1) | 2018 (52.7) | |
IV | 1119 (4.5) | 225 (3.7) | 276 (4.7) | 135 (3.5) | |
Unknown | 10216 | 2112 | 1158 | 943 | |
Histology | <0.0001 | ||||
IDC | 26 973 (76.8) | 6227 (75.8) | 5441 (77.0) | 3793 (79.5) | |
ILC | 1170 (3.3) | 194 (2.4) | 186 (2.6) | 97 (2.0) | |
IDC and ILC | 1522 (4.3) | 231 (2.8) | 337 (4.8) | 194 (4.1) | |
Other | 5436 (15.5) | 1563 (19.0) | 1103 (15.6) | 686 (14.4) | |
Oestrogen receptor status | <0.0001a | ||||
Positive | 13 362 (62.0) | 2667 (49.9) | 3035 (57.8) | 2379 (67.8) | |
Negative | 8010 (37.2) | 2636 (49.3) | 2185 (41.7) | 1115 (31.7) | |
Borderline | 172 (0.8) | 42 (0.8) | 26 (0.5) | 17 (0.5) | |
Unknown | 13 557 | 2870 | 1821 | 1259 | |
Progesterone receptor status | <0.0001a | ||||
Positive | 11 995 (56.3) | 2280 (43.2) | 2606 (50.5) | 2180 (63.1) | |
Negative | 9117 (42.8) | 2941 (55.8) | 2514 (48.7) | 1241 (35.9) | |
Borderline | 198 (0.9) | 51 (1.0) | 41 (0.8) | 35 (1.0) | |
Unknown | 13 791 | 2943 | 1906 | 1314 | |
Adjuvant radiation therapy | <0.0001 | ||||
No | 21 357 (60.8) | 5105 (62.1) | 4206 (59.5) | 2722 (57.1) | |
Yes | 13 744 (39.2) | 3110 (37.9) | 2861 (40.5) | 2048 (42.9) | |
Adjuvant radiation therapy after SM | <0.0001 | ||||
No | 3576 (30.2) | 1107 (37.8) | 971 (37.6) | 532 (30.0) | |
Yes | 8259 (69.8) | 1822 (62.2) | 1613 (62.4) | 1243 (70.0) | |
Adjuvant radiation therapy after TM | <0.0001 | ||||
No | 16 318 (75.1) | 3331 (72.7) | 2721 (68.9) | 1984 (71.4) | |
Yes | 5413 (24.9) | 1253 (27.3) | 1227 (31.1) | 796 (28.6) |
